A Phase 3 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 63 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-03.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.
Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 47th largest by enrollment of the 227 interventional ones that give a count, is one of 12 that started in 2009, is one of 45 in phase 3, and was the 106th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Biostar Pharma, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 146 · Phase 3 55 · Phase 4 6
First in 1998; this study’s year is marked. 12 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 287 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 54 across the 227 interventional studies. Of the 149 that completed or were terminated, 54 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 233 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 56th largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 61 in phase 3, and was the 52nd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing capecitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06016387Sunnybrook Health Sciences CentreTucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | 2026-12-31 |
| NCT06764940Biostar Pharma, Inc.A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | 2027-01-15 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
| NCT06247995Novartis PharmaceuticalsA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | 2027-04-14 |
Add all 8 to your calendar (.ics) → With an account.
Among the 233 studies testing capecitabine in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line therapy with docetaxel + Avastin. Eligible patients will receive up to 6 x 3 week cycles of treatment with Avastin (15 mg/mg IV on Day 1 of each cycle) + docetaxel (75-100 mg/m2 IV on Day 1 of each cycle). Those patients who do not progress will be randomized to 3 week cycles of either a) Avastin (15 mg/kg IV on Day 1 of each cycle) + Xeloda (1000 mg/m2 po bid on Days 1-14 of each cycle) or b) Avastin alone. Study treatment will continue until disease progression, unacceptable toxicity, patient request for withdrawal or end of study, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin]
Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda]
15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)
Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST). Progressive Disease (PD) was defined as a 20 percent (%) or greater increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions.
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)
PFS was defined as the time from first study drug dosing to the first documented disease progression or death, whichever occurred first.Time to progression was defined as the time from randomization to the first documented disease progression defined per RECIST 1.0 criteria. Participants without an event at data cut-off or who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression free. Participants who took other non-protocol anti-cancer drugs while being on study medication, and who were still event free were censored on the date of first dose of the anti-cancer drug. Participants without post-randomization tumor assessments but alive were censored at the time of randomization. Participants without post-randomization assessments, who died after randomization were considered to have the PFS event at date of death. Kaplan-Meier estimation was used for median time to PFS
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)
Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Progressive disease (PD) was defined as 20% increase in the sum of the longest diameter of target lesions and SD was defined as small changes that do not meet above criteria. Pearson-Clopper one-sample method was used for Confidence intervals (CIs).
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)
CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Overall Survival (Maintenance Phase Data Cutoff October 4, 2013)
Duration of Overall Survival (OS) was defined as the time from randomization to death of any cause. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. Kaplan Meier estimation was used to determine OS.
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Percentage of Participants Expected to Be Alive After 1 and 2 Years on Treatment (Maintenance Phase Data Cutoff October 4, 2013)
Probability of being alive after 1 and 2 years on treatment with 95% CIs was calculated using Kaplan Meier approach with LOGLOG transformation.
Time frame: Years 1 and 2
Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)
PD was defined per RECIST 1.0 as 20% increase in the sum of the longest diameter of target lesions.
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013
Time To Progression (Maintenance Phase Data Cutoff October 4, 2013)
Time to Progression was defined as the time from randomization to the first documented disease progression (using investigator assessments of disease progression by RECIST 1.0). PD was defined as 20% increase in the sum of the longest diameter of target lesions.
Time frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013
Quality of Life Assessed As Change From Baseline in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - 30 (EORTC QLQ - C30) (Maintenance Phase Data Cutoff October 4, 2013)
The EORTC QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase.
Time frame: Baseline, Randomization and Cycles 3, 6, 9 and 12
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)
Objective Response was determined by the investigator using RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Pearson-Clopper one-sample method was used for CI.
Time frame: Screening and at the end of every third cycle until randomization for an average of 18 weeks
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)
CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.
Time frame: Screening and at the end of every third cycle until randomization for an average of 18 weeks
| Milestone | Initial Treatment Phase: Bevacizumab Plus (+) Docetaxel | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|---|
| Started | 284 | 0 | 0 |
| Completed | 185 | 0 | 0 |
| Not completed | 99 | 0 | 0 |
| Withdrew: Adverse event | 31 | 0 | 0 |
| Withdrew: Disease progression | 41 | 0 | 0 |
| Withdrew: Withdrawal by subject | 13 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Health authority/study termination | 3 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 |
| Milestone | Initial Treatment Phase: Bevacizumab Plus (+) Docetaxel | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|---|
| Started | 0 | 94 | 91 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 94 | 91 |
| Withdrew: Disease progression | 0 | 73 | 60 |
| Withdrew: Adverse event | 0 | 9 | 12 |
| Withdrew: Withdrawal by subject | 0 | 2 | 6 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Health authority/study termination | 0 | 1 | 2 |
| Withdrew: Physician decision | 0 | 2 | 1 |
| Withdrew: Change of treatment | 0 | 4 | 0 |
| Withdrew: Treatment ongoing at study closure | 0 | 0 | 10 |
| Withdrew: Participant not treated | 0 | 2 | 0 |
Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST). Progressive Disease (PD) was defined as a 20 percent (%) or greater increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions.
| percentage of participants | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013) | 88.3 | 75.8 |
PFS was defined as the time from first study drug dosing to the first documented disease progression or death, whichever occurred first.Time to progression was defined as the time from randomization to the first documented disease progression defined per RECIST 1.0 criteria. Participants without an event at data cut-off or who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression free. Participants who took other non-protocol anti-cancer drugs while being on study medication, and who were still event free were censored on the date of first dose of the anti-cancer drug. Participants without post-randomization tumor assessments but alive were censored at the time of randomization. Participants without post-randomization assessments, who died after randomization were considered to have the PFS event at date of death. Kaplan-Meier estimation was used for median time to PFS
| months | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013) | 4.3 (3.9 to 6.8) | 11.9 (9.8 to 15.4) |
Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Progressive disease (PD) was defined as 20% increase in the sum of the longest diameter of target lesions and SD was defined as small changes that do not meet above criteria. Pearson-Clopper one-sample method was used for Confidence intervals (CIs).
| percentage of participants | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013) | 76.6 (66.7 to 84.7) | 85.7 (76.8 to 92.2) |
CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.
| percentage of participants | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013) | 97.9 (92.5 to 99.7) | 98.9 (94.0 to 100.0) |
| percentage of participants | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013) | 56.4 | 36.3 |
Duration of Overall Survival (OS) was defined as the time from randomization to death of any cause. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. Kaplan Meier estimation was used to determine OS.
| months | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Overall Survival (Maintenance Phase Data Cutoff October 4, 2013) | 23.7 (18.5 to 31.7) | 39.0 (32.3 to NA) |
Probability of being alive after 1 and 2 years on treatment with 95% CIs was calculated using Kaplan Meier approach with LOGLOG transformation.
| percentage of participants | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| 1 Year | 71.6 (61.1 to 79.7) | 90.4 (81.8 to 95.1) |
| 2 Years | 49.4 (38.5 to 59.3) | 69.0 (57.6 to 77.9) |
PD was defined per RECIST 1.0 as 20% increase in the sum of the longest diameter of target lesions.
| percentage of participants | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013) | 88.3 | 74.7 |
Time to Progression was defined as the time from randomization to the first documented disease progression (using investigator assessments of disease progression by RECIST 1.0). PD was defined as 20% increase in the sum of the longest diameter of target lesions.
| months | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Time To Progression (Maintenance Phase Data Cutoff October 4, 2013) | 4.3 (3.9 to 6.8) | 11.9 (9.8 to 15.4) |
The EORTC QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase.
| units on a scale | Maintenance Phase: Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|
| Randomization (n= 83, 86) | -3.51 (-9.63 to 2.60) | -4.46 (-9.40 to 0.48) |
| Cycle 3 (n= 44, 52) | 0.76 (-6.65 to 8.17) | -3.21 (-9.99 to 3.58) |
| Cycle 6 (n= 26, 54) | 4.17 (-6.49 to 14.82) | -5.40 (-11.67 to 0.87) |
| Cycle 9 (n= 18, 37) | 8.80 (-4.57 to 22.17) | -1.80 (-8.92 to 5.32) |
| Cycle 12 (n= 12, 31) | 0.69 (-17.99 to 19.37) | 0.00 (-8.24 to 8.24) |
Objective Response was determined by the investigator using RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Pearson-Clopper one-sample method was used for CI.
| percentage of participants | Initial Treatment Phase: Bevacizumab + Docetaxel |
|---|---|
| Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase) | 8.8 (4.1 to 16.1) |
CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.
| percentage of participants | Initial Treatment Phase: Bevacizumab + Docetaxel |
|---|---|
| Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase) | 56.9 (46.7 to 66.6) |
Collected over Adverse Events (AEs) were recorded from the date of randomization until the end of study at the cutoff date of October 4, 2013.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Treatment Phase:Bevacizumab + Docetaxel | — | 78/284 (27.5%) | 40/284 (14.1%) |
| Maintenance Phase:Bevacizumab | — | 7/92 (7.6%) | 4/92 (4.3%) |
| Maintenance Phase: Bevacizumab + Capecitabine | — | 10/91 (11%) | 32/91 (35.2%) |
| Event | Initial Treatment Phase:Bevacizumab + Docetaxel | Maintenance Phase:Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 28/284 | 0/92 | 0/91 |
| NeutropeniaBlood and lymphatic system disorders | 17/284 | 0/92 | 0/91 |
| Myocardial infarctionCardiac disorders | 0/284 | 0/92 | 2/91 |
| GastroenteritisInfections and infestations | 2/284 | 2/92 | 0/91 |
| PneumoniaInfections and infestations | 5/284 | 1/92 | 0/91 |
| Mucosal inflammationGeneral disorders | 4/284 | 0/92 | 0/91 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/284 | 0/92 | 1/91 |
| Respiratory tract infectionInfections and infestations | 1/284 | 0/92 | 1/91 |
| InfectionInfections and infestations | 0/284 | 0/92 | 1/91 |
| DysphagiaGastrointestinal disorders | 0/284 | 0/92 | 1/91 |
| Event | Initial Treatment Phase:Bevacizumab + Docetaxel | Maintenance Phase:Bevacizumab | Maintenance Phase: Bevacizumab + Capecitabine |
|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 6/284 | 0/92 | 29/91 |
| NeutropeniaBlood and lymphatic system disorders | 29/284 | 1/92 | 2/91 |
| HypertensionVascular disorders | 5/284 | 3/92 | 7/91 |
Initial Phase Intent-to-Treat (ITT) population: all participants who were enrolled.
| Age, Continuous(years) | Intial Treatment Phase: Bevacizumab + Docetaxel |
|---|---|
| Mean | 52.5 ± 11.8 |
| Sex: Female, Male(Participants) | Intial Treatment Phase: Bevacizumab + Docetaxel |
|---|---|
| Female | 287 |
| Male | 0 |
The record gives a start of Jul 2009, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capecitabine